FDA Label Update Shortens Initial Monitoring for Tarlatamab in Extensive-Stage Small Cell Lung Cancer

The FDA has updated the label for tarlatamab, a treatment for extensive-stage small cell lung cancer, to shorten the initial monitoring period. This regulatory change aims to support broader access to the treatment by making it more feasible to administer in community practices, potentially allowing more patients to receive care closer to home.